Peter Martin Hotten

NXXI, Inc. operates as a nutritional bioscience company. It primarily develops and markets raw materials, formulations, compounds, blends and bulk and other materials to third-party non-end users to be further fabricated, blended or packaged for ultimate sales to end-users as nutritional supplements. The company was founded on June 29, 1983 and is headquartered in Purchase, NY.

ANGLE Technology Ltd. provides management consulting and venture capital services.

NeuroTargets, Inc. develops novel therapeutic products. It discovers and develops new drugs for neurological diseases. The company develops products in the fields of diabetic neuropathy, pain resulting from nerve damage, spinal cord injuries and other trauma, and brain diseases associated with cognitive impairment such as stroke and Alzheimer's disease. NeuroTargets was founded in 1999 and is located at Guildford, UK.

Momentum Bioscience Ltd. develops a technology for the detection of infection in blood and other normally sterile body fluids. Its solutions include EMA Sepsis, a detection method for organisms in blood; EMA Total, a detection method for organisms in NSF; EMA Bacteria for the detection of bacteria; and EMA Fungi for the detection of fungi. The company was founded by William Henry Mullen in 2008 and is headquartered in Cardiff, the United Kingdom.